Paramount

Researchers are evaluating the effects of Taplucainium Inhalation Powder (NOC-110) in adults aged 18 to 80 who have refractory or unexplained chronic cough lasting at least 12 months. This phase 2b study aims to assess the medicine's efficacy, safety, and tolerability compared to a placebo in a randomized, double-blind, controlled setting. The study will involve about 455 participants, with up to 1264 screened to identify eligible adults. Participants will receive either NOC-110 inhalation powder or a matching placebo once daily during the treatment period. The study includes a screening phase followed by approximately 13 weeks of participation, during which participants will use the assigned inhalation powder. The trial is designed to monitor how the treatments impact cough frequency and overall tolerability over this period. Throughout the study, participants will be closely monitored for changes in their 24-hour cough rates, measured from baseline to the end of treatment. Researchers will also assess safety and any side effects. Participants will provide informed consent and follow contraceptive guidance if applicable. The study includes detailed tracking of medical history, respiratory health, and other relevant factors to ensure participant safety and gather comprehensive data on treatment effects.

Researchers are studying the effects of eluxadoline in children aged 6 to 17 years who have irritable bowel syndrome with diarrhea (IBS-D). This Phase 2 trial aims to explore how eluxadoline may help treat IBS-D symptoms in this age group, understand how the drug behaves in the body, and assess its safety and tolerability. Enrollment for children aged 12 to 17 has closed, but younger children aged 6 to 11 are still being enrolled. Participants will receive either oral eluxadoline tablets or matching placebo tablets. The study is randomized, double-blind, placebo-controlled, and dose-ranging, meaning neither the participants nor researchers know who receives the drug or placebo, and different doses may be tested. The trial includes multiple visits where treatments are administered, but specific dosing schedules are not detailed in the summary. Children taking part will complete electronic diaries to record symptoms like abdominal pain and stool consistency. Researchers will track changes in stool consistency over a 4-week treatment period compared to before treatment. Safety and tolerability will also be monitored throughout, with assessments including symptom evaluations and adherence to the diary. The total duration and further follow-up details are not specified.